CD8A and neoplasm: Strikingly, we observed a higher CD8+/CD4+ ratio in lexatumumab + ROCK1i and lexatumumab + avelumab‐treated 4T1 tumors but not in DR5 agonist alone treated tumors (Fig 6C, Appendix S10, n = 6–20 tumor‐bearing animals, three separate experiments).